All rights reserved. No reuse allowed without permission.

1	
2	Deciphering causal proteins in Alzheimer's disease: A novel Mendelian randomization
3	method integrated with AlphaFold3 for 3D structure prediction
4	Minhoo Vool Come W. Millor? Dodri N. Vondonojon ³ Androo A. Doooonolli ⁴
5 6	Zijian Guo ⁵ *, Zhonghua Liu ⁶ *
7	
8 9	¹ Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong
10	² Department of Environmental Health Sciences, Columbia University, New York, NY,
11	USA
12	³ Taub Institute on Alzheimer's Disease and the Aging Brain, Department of
13	Neurology, Columbia University,
14	New York, NY, USA.
15	⁴ Department of Environmental Health, Harvard T.H. Chan School of Public Health,
16	Boston, MA, USA
17	⁵ Department of Statistics, Rutgers University, Piscataway, NJ, USA.
18	^o Department of Biostatistics, Columbia University, New York, NY, USA.
20 18	* Correspondence to: Zijian Guo (zijano@stat rutgers edu) or Zhonghua Liu (Lead
20 21	contact $z/2509$ cume columbia edu)
22	contact, <u>212007(a)cante.cotamota.cau</u>)
23	Summary
24	Hidden confounding biases hinder identifying causal protein biomarkers for
25	Alzheimer's disease in non-randomized studies. While Mendelian randomization (MR)
26	can mitigate these biases using protein quantitative trait loci (pQTLs) as instrumental
27	variables, some pQTLs violate core assumptions, leading to biased conclusions. To
28	address this, we propose MR-SPI, a novel MR method that selects valid pQTL
29	instruments using the Anna Karenina Principle and performs robust post-selection
30	inference. Integrating MR-SPI with AlphaFold3, we developed a computational
31	pipeline to identify causal protein biomarkers and predict 3D structural changes.
32	Applied to genome-wide proteomics data from 54,306 UK Biobank participants and
33	455,258 subjects (71,880 cases and 383,378 controls) for a genome-wide association
34	study of Alzheimer's disease, we identified seven proteins (TREM2, PILRB, PILRA,
35	EPHA1, CD33, RET, and CD55) with structural alterations due to missense mutations.
36	These findings offer insights into the etiology and potential drug targets for Alzheimer's
37	disease.
38	
39	

40 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 **1. Introduction**

Alzheimer's disease (AD) stands as the primary cause of dementia globally, exerting a 42 considerable strain on healthcare resources^{1,2}. Despite extensive efforts, the etiology 43 and pathogenesis of AD are still unclear, and strategies aimed at impeding or delaying 44 its clinical advancement have largely remained challenging to achieve^{1,3,4}. The amyloid 45 cascade hypothesis posits that AD begins with the accumulation and aggregation of 46 amyloid-beta (A β) peptides in the brain, culminating in the formation of β -amyloid 47 fibrils, leading to tau hyperphosphorylation, neurofibrillary tangle formation and 48 neurodegeneration^{5,6}. However, current AD therapies targeting AB production and 49 amyloid formation offer only transient symptomatic relief and fail to halt disease 50 progression, resulting in a lack of effective drugs for AD^{1,7}. Therefore, it is imperative 51 and urgent to identify causal protein biomarkers to elucidate the underlying 52 mechanisms of AD, and to expedite the development of effective therapeutic 53 interventions for AD. 54

55

In causal inference, randomized controlled trials (RCTs) serve as the gold standard for 56 evaluating the causal effect of an exposure on the health outcome of interest. However, 57 it might be neither feasible nor ethical to perform RCTs where protein levels are 58 considered as the exposures. Mendelian randomization (MR) leverages the random 59 60 assortment of genes from parents to offspring to mimic RCTs to establish causality in non-randomized studies⁸⁻¹⁰. MR uses genetic variants, typically single-nucleotide 61 polymorphisms (SNPs), as instrumental variables (IVs) to assess the causal association 62 between an exposure and a health outcome¹¹. Recently, many MR methods have been 63 developed to investigate causal relationships using genome-wide association study 64 (GWAS) summary statistics data that consist of effect estimates of SNP-exposure and 65 66 SNP-outcome associations from two sets of samples, which are commonly referred to as the two-sample MR designs¹²⁻¹⁵. Since summary statistics are often publicly 67 available and provide abundant information of associations between genetic variants 68 69 and complex traits/diseases, two-sample MR methods become increasingly popular^{14,16-} ¹⁸. In particular, recent studies with large-scale proteomics data have unveiled numerous 70 protein quantitative traits loci (pQTLs) associated with thousands of proteins^{19,20}, 71 72 facilitating the application of two-sample MR methods, where pQTLs serve as IVs and protein levels serve as exposures, to identify proteins as causal biomarkers for complex 73 traits and diseases. 74

75

To employ MR for identifying causal protein biomarkers, conventional MR methods 76

require the pQTLs included in the analysis to be valid IVs for reliable causal inference. 77

A pQTL is called a valid IV if the following three core IV assumptions hold^{9,21}: 78

- 79
- **Relevance**: The pQTL is associated with the protein; (A1).
- 80 81
- Effective Random Assignment: The pQTL is not associated with any (A2). unmeasured confounder of the protein-outcome relationship; and
- 82 83

(A3). **Exclusion Restriction**: The pQTL affects the outcome only through the protein in view.

Among the three core IV assumptions (A1) - (A3), only the first assumption (A1) can 84 be tested empirically by selecting pQTLs significantly associated with the protein. 85 86 However, assumptions (A2) and (A3) cannot be empirically verified in general and may be violated in practice, which may lead to a biased estimate of the causal effect. For 87 example, violation of (A2) may occur due to the presence of population stratification^{9,22}; 88 and violation of (A3) may occur in the presence of horizontal pleiotropy 9,23 , which is a 89 widespread biological phenomenon that the pQTL IV affects the outcome through other 90 biological pathways that do not involve the protein in view, for example, through 91 alternative splicing or micro-RNA effects²⁴⁻²⁶. 92

93

Recently, several MR methods have been proposed to handle invalid IVs under certain 94 95 assumptions, as summarized in Table 1. Some of these additional assumptions for the 96 identification of the causal effect in the presence of invalid IVs are listed below:

- 97 The Instrument Strength Independent of Direct Effect (InSIDE) assumption: the (i) pQTL-protein effect is asymptotically independent of the horizontal pleiotropic 98 effect when the number of pQTL IVs goes to infinity. For example, the random-99 effects inverse-variance weighted (IVW) method²⁷, MR-Egger²⁸, MR-RAPS 100 (Robust Adjusted Profile Score)¹⁶, and the Mendelian randomization pleiotropy 101 residual sum and outlier (MR-PRESSO) test²⁹. 102
- (ii) Majority rule condition: up to 50% of the candidate pOTL IVs are invalid. For 103 example, the weighted median method³⁰ and MR-PRESSO. 104
- (iii) Plurality rule condition or the ZEro Modal Pleiotropy Assumption (ZEMPA)^{15,31}: 105 a plurality of the candidate IVs are valid, which is weaker than the majority rule 106 condition. For example, the mode-based estimation³¹, MRMix³² and the 107 contamination mixture method³³. 108
- (iv) Other distributional assumptions. For example, MRMix and the contamination 109 mixture method impose normal mixture distribution assumption on the genetic 110

- associations and the ratio estimates, respectively. 111
- 112

Despite many existing efforts, current MR methods still face new challenges when 113 dealing with pQTLs IVs for analyzing proteomics data. First, it's worth noting that the 114 number of pQTLs for each protein tends to be small. For example, in two proteomics 115 studies, the median number of pQTLs per protein is $4^{20,34}$. With such a limited number 116 of IVs, those MR methods based on the InSIDE assumption which requires a large 117 number of IVs or other distributional assumptions might yield unreliable results in the 118 presence of invalid IVs^{15,28}. Second, current MR methods require an ad-hoc set of pre-119 determined genetic IVs, which is often obtained by selecting genetic variants with 120 strong pQTL-protein associations in proteomics data³⁵. Since such traditional way of 121 122 selecting IVs only requires the proteomics data, hence the same set of selected IVs is used for assessing the causal relationships between the protein in view and different 123 health outcomes. Obviously, this one-size-fits-all strategy for selecting IVs might not 124 work well for different outcomes because the underlying genetic architecture may vary 125 across outcomes. For example, the pattern of horizontal pleiotropy might vary across 126 127 different outcomes. Therefore, it is desirable to develop an automatic and computationally efficient algorithm to select a set of valid genetic IVs for a specific 128 protein-outcome pair to perform reliable causal inference, especially when the number 129 130 of candidate pQTL IVs is small.

131

132 In this paper, we develop a novel all-in-one pipeline for causal protein biomarker identification and 3D structural alteration prediction using large-scale genetics, 133 proteomics and phenotype/disease data, as illustrated in Figure 1. Specifically, we 134 propose a two-sample MR method and algorithm that can automatically Select valid 135 136 pQTL IVs and then performs robust Post-selection Inference (MR-SPI) for the causal 137 effect of proteins on the health outcome of interest. The key idea of MR-SPI is based on the Anna Karenina Principle which states that all valid instruments are alike, while 138 139 each invalid instrument is invalid in its own way – paralleling Leo Tolstoy's dictum that "all happy families are alike; each unhappy family is unhappy in its own way"³⁶. In 140 other words, valid instruments will form a group and should provide similar ratio 141 estimates of the causal effect, while the ratio estimates of invalid instruments are more 142 likely to be different from each other. With the application of MR-SPI, we can not only 143 identify the causal protein biomarkers associated with disease outcomes, but can also 144 obtain missense genetic variations (used as pQTL IVs) for those identified causal 145

proteins. These missense pQTL IVs will induce changes of amino acids, leading to 3D 146 structural changes of these proteins. A classic example of a missense mutation was 147 found in sickle cell disease, where the mutation at SNP rs334, located on chromosome 148 11 (11p15.4), results in the change of codon 6 of the beta globin chain from [GAA] to 149 [GTA] ³⁷⁻³⁹. This substitution leads to the replacement of glutamic acid with valine at 150 position 6 of the beta chain of the hemoglobin protein, altering the structure and 151 function of hemoglobin protein. Consequently, red blood cells assume a crescent or 152 sickle-shaped morphology, impairing blood flow to various parts of the body^{40,41}. 153 Moreover, to further offer novel biological insights into the interpretation of the causal 154 effect at the molecular level, we incorporate AlphaFold3⁴²⁻⁴⁵ into our pipeline to predict 155 156 the 3D structural alteration resulting from the corresponding missense pQTL IVs for the causal proteins identified by MR-SPI. Our pipeline can elucidate the mechanistic 157 underpinnings of how missense genetic variations translate into 3D structural 158 alterations at the protein level, thereby advancing our understanding of disease etiology 159 and potentially informing targeted therapeutic interventions. 160

161

Our pioneering pipeline for the first time integrates the identification of causal protein 162 biomarkers for health outcomes and the subsequent analysis of their 3D structural 163 alterations into a unified framework, leveraging increasingly publicly available GWAS 164 165 summary statistics for health research. Within our framework, the proposed MR-SPI 166 serves dual purposes: (1) identifying causal protein biomarkers; and (2) selecting valid missense pQTL IVs for subsequent 3D structural analysis. Compared to existing two-167 sample MR methods, MR-SPI is the first MR method that utilizes both exposure and 168 outcome data to automatically select a set of valid IVs, especially when the number of 169 candidate IVs is small in proteomics data, which is a prominent challenge with no 170 171 satisfactory solution up to date. We note that while MR-PRESSO also selects valid IVs 172 for MR analysis, it requires both the stronger majority rule condition and the InSIDE assumption, as well as a minimum number of four candidate IVs for implementation²⁹. 173 174 In contrast, our proposed MR-SPI does not require the InSIDE assumption and only requires the plurality rule condition that is weaker than the majority rule condition, and 175 only requires a minimum number of three IVs for the proposed voting procedure. 176 Therefore, MR-SPI is more suitable for analyzing proteomics data. Extensive 177 simulations show that our MR-SPI method outperforms other competing MR methods 178 under the plurality rule condition. We employ MR-SPI to perform omics MR (xMR) 179 with 912 plasma proteins using the large-scale UK Biobank proteomics data in 54,306 180

UK Biobank participants²⁰ and find 7 proteins significantly associated with the risk of 181 Alzheimer's disease. We further use AlphaFold3⁴²⁻⁴⁵ to predict the 3D structural 182 alterations of these 7 proteins due to missense genetic variations, and then illustrate the 183 structural alterations graphically using the PyMOL software (https://pymol.org), 184 providing new biological insights into their functional roles in AD development and 185 186 may aid in identifying potential drug targets.

187

2. Results 188

2.1 Overview of the pipeline 189

Our proposed all-in-one pipeline for the identification and 3D structural alteration 190 191 prediction of causal protein biomarkers consists of three primary steps, as illustrated in Figure 1. First, for each protein biomarker, we employ our proposed MR-SPI to select 192 valid pQTL IVs by incorporating the proteomics GWAS and disease outcome GWAS 193 summary data together, and then estimate the causal effect of each protein on the 194 outcome using the selected valid pQTL IVs. The main idea and more detailed 195 implementation steps for MR-SPI is described in Section 2.2. Second, we perform 196 Bonferroni correction⁴⁶ for the p-values of the estimated causal effects to identify 197 putative causal protein biomarkers associated with the outcome. Third, for each 198 identified protein, we apply AlphaFold3 to predict and compare the 3D structures of 199 200 both the wild-type protein and mutated protein resulting from missense pQTL IVs.

201

2.2 MR-SPI selects valid genetic instruments by a voting procedure 202

MR-SPI is an automatic procedure to select valid pQTL instruments and perform robust 203 causal inference using two-sample GWAS and proteomics data. In summary, MR-SPI 204 consists of the following four steps, as illustrated in Figure 2: 205

206

(1). select relevant pQTL IVs that are strongly associated with the protein;

- (2). each relevant pQTL IV provides a ratio estimate of the causal effect, and then 207 all the other relevant pOTL IVs votes for it to be a valid IV if their degrees of 208 violation of assumptions (A2) and (A3) are smaller than a data-dependent 209 210 threshold as in equation (4);
- (3). select valid pQTL IVs by majority/plurality voting or by finding the maximum 211 clique of the voting matrix that encodes whether two relevant pOTL IVs 212 mutually vote for each other to be valid (the voting matrix is defined in 213 equation (6) in STAR (structured, transparent, accessible reporting) Methods); 214
- (4). estimate the causal effect using the selected valid pQTL IVs and construct a 215

216 217 robust confidence interval with guaranteed nominal coverage even if in the presence of possible IV selection error in finite samples.

218

Most current two-sample MR methods only use step (1) to select (relevant) pQTL 219 instruments for downstream MR analysis, while the selected pQTL instruments might 220 221 violate assumptions (A2) and (A3), leading to possibly unreliable scientific findings. To address this issue, MR-SPI automatically select valid pQTL instruments for a 222 specific protein-outcome pair by further incorporating the outcome GWAS data. Our 223 key idea of selecting valid pQTL instruments is that, under the plurality rule condition, 224 valid IVs will form the largest group and should give "similar" ratio estimates according 225 226 to the Anna Karenina Principle (see STAR Methods). More specifically, we propose the 227 following two criteria to measure the similarity between the ratio estimates of two 228 pQTLs i and k in step (2):

229 230

231 232

233

234

C1 We say the kth pQTL "votes for" the *j*th pQTL to be a valid IV if, by assuming the *j*th pQTL is valid, the *k*th pQTL's degree of violation of assumptions (A2) and (A3) is smaller than a data-dependent threshold as in equation (4);

C2 We say the ratio estimates of two pQTLs i and k are "similar" if they mutually vote for each other to be valid.

235

236 In step (3), we construct a symmetric binary voting matrix to encode the votes that each 237 relevant pQTL receives from other relevant pQTLs: the (k, j) entry of the voting matrix is 1 if pQTLs *j* and *k* mutually vote for each other to be valid, and 0 otherwise. 238 We propose two ways to select valid pQTL IVs based on the voting matrix (see STAR 239 Methods): (1) select relevant pQTLs who receive majority voting or plurality voting as 240 valid IVs; and (2) use pQTLs in the maximum clique of the voting matrix as valid IVs^{47} . 241 242 Our simulation studies show that the maximum clique method can empirically offer lower false discovery rate (FDR)⁴⁸ and higher true positive proportion (TPP) as shown 243 in Table S4 and Supplementary Section S6. 244

245

In step (4), we estimate the causal effect by fitting a zero-intercept ordinary least 246 squares regression of pOTL-outcome associations on pOTL-protein associations using 247 the set of selected valid pOTL IVs, and then construct a standard confidence interval 248 for the causal effect using standard linear regression theory. In finite samples, some 249 invalid IVs with small (but still nonzero) degrees of violation of assumptions (A2) and 250

(A3) might be incorrectly selected as valid IVs, commonly referred to as "locally 251 invalid IVs"⁴⁹. To address this possible issue, we propose to construct a robust 252 confidence interval with a guaranteed nominal coverage even in the presence of IV 253 selection error in finite-sample settings using a searching and sampling method⁴⁹, as 254 described in Supplementary Figure S17 and STAR Methods. 255

256

2.3 Comparing MR-SPI to other competing MR methods in simulation studies 257

258 We conduct extensive simulations to evaluate the performance of MR-SPI in the presence of invalid IVs. We simulate data in a two-sample setting under four setups: 259 (S1) majority rule condition holds, and no locally invalid IVs exist; (S2) plurality rule 260 261 condition holds, and no locally invalid IVs exist; (S3) majority rule condition holds, and locally invalid IVs exist; (S4) plurality rule condition holds, and locally invalid IVs 262 exist. More detailed simulation settings are described in STAR Methods. We compare 263 MR-SPI to the following competing MR methods: (1) the random-effects IVW 264 method²⁷, (2) MR-RAPS¹⁶, (3) MR-PRESSO²⁹, (4) the weighted median method³⁰, (5) 265 the mode-based estimation³¹, (6) MRMix³², and (7) the contamination mixture 266 267 method³³. We exclude MR-Egger in this simulation since it is heavily biased in our simulation settings. For simplicity, we shall use IVW to represent the random-effects 268 IVW method hereafter. 269

270

In Figure 3, we present the percent bias, empirical coverage, and average lengths of 95% 271 272 confidence intervals of those MR methods in simulated data with a sample size of 5,000 for both the exposure and the outcome. Additional simulation results under a range of 273 sample sizes (n=5,000, 10,000, 20,000, 40,000, 80,000) can be found in Supplementary 274 Figure S1 and Tables S1-S3. When the plurality rule condition holds and no locally 275 276 invalid IVs exist, MR-SPI has small bias and short confidence interval, and the 277 empirical coverage can attain the nominal level. When locally invalid IVs exist, the standard confidence interval might suffer from finite-sample IV selection error, and 278 279 thus the empirical coverage is lower than 95% if the sample sizes are not large (e.g., 5,000). In practice, we can perform sensitivity analysis of the causal effect estimate by 280 changing the threshold in the voting step (see STAR Methods and Supplementary 281 Figure S14). If the causal effect estimate is sensitive to the choice of the threshold, then 282 there might exists finite-sample IV selection error. In such cases, the proposed robust 283 confidence interval of MR-SPI can still attain the 95% coverage level and thus is 284 recommended for use. We also examine the performance of MR-SPI in overlapped 285

samples mimicking real data settings with simulation set-up and results given in 286 Supplementary Section S8, and we find that our MR-SPI can still provide valid 287 statistical inference. 288

289

2.4 Identifying plasma proteins associated with the risk of Alzheimer's disease 290

Omics MR (xMR) aims to identify omics biomarkers (e.g., proteins) causally associated 291 with complex traits and diseases. In particular, xMR with proteomics data enables the 292 identification of disease-associated proteins, facilitating crucial advancements in 293 disease diagnosis, monitoring, and novel drug target discovery. In this section, we apply 294 MR-SPI to identify putative causal plasma protein biomarkers associated with the risk 295 of Alzheimer's disease (AD). The proteomics data used in our analysis comprises 296 54,306 participants from the UK Biobank Pharma Proteomics Project (UKB-PPP)²⁰. In 297 the UKB-PPP consortium, up to 22.6 million imputed autosomal variants across 1,463 298 proteins post quality control were analyzed, discovering 10,248 primary associations 299 through LD (Linkage Disequilibrium) clumping ± 1 Mb around the significant variants, 300 including 1,163 in the *cis* region and 9,085 in the *trans* region²⁰. As described in Sun, 301 et al.²⁰, the following filtering steps are used to retain pQTLs in the UKB-PPP summary 302 level proteomics data: (1)genome-wide significant (p-value < 3.40×10^{-11}), after 303 Bonferroni correction; and (2) independent pQTLs using LD clumping ($r^2 < 0.01$). 304 Thus, all these candidates pQTL IVs are independent and strongly associated with the 305 306 proteins. Summary statistics for AD are obtained from a meta-analysis of GWAS 307 studies for clinically diagnosed AD and AD-by-proxy, comprising 455,258 samples in total⁵⁰. For MR method comparison, we analyze 912 plasma proteins that share four or 308 more candidate pQTLs within the summary statistics for AD, because the 309 implementation of MR-PRESSO requires a minimum of four candidate IVs ²⁹. 310

311

As presented in Figure 4(A), MR-SPI identifies 7 proteins that are significantly 312 associated with AD after Bonferroni correction, including CD33, CD55, EPHA1, 313 314 PILRA, PILRB, RET, and TREM2. The detailed information of the selected pQTL IVs for these 7 proteins can be found in Supplementary Table S6. Among them, four 315 proteins (CD33, PILRA, PILRB, and RET) are positively associated with the risk of 316 AD while the other three proteins (CD55, EPHA1, and TREM2) are negatively 317 associated with the risk of AD. We also note that some competing MR methods may 318 detect additional proteins, which are likely spurious due to invalid pQTL IVs, as 319 demonstrated in Supplementary Section 11. Previous studies have revealed that some 320

of those 7 proteins and the corresponding protein-coding genes might contribute to the 321 pathogenesis of AD⁵¹⁻⁵⁶, as shown in Supplementary Table S8. For example, it has been 322 found that CD33 plays a key role in modulating microglial pathology in AD, with 323 TREM2 acting downstream in this regulatory pathway⁵³. Besides, a recent study has 324 shown that a higher level of soluble TREM2 is associated with protection against the 325 progression of AD pathology⁵⁷. Additionally, RET at mitochondrial complex I is 326 activated during ageing, which might contribute to an increased risk of ageing-related 327 diseases including AD⁵⁵. Using the UniProt database⁵⁸, we also find that genes encoding 328 these 7 proteins are overexpressed in tissues including hemopoietic tissues and brain, 329 as well as cell types including microglial, macrophages and dendritic cells. These 330 331 findings highlight the potential therapeutic opportunities that target these proteins for the treatment of AD. Furthermore, in the Therapeutic Target Database (TTD)⁵⁹ and 332 DrugBank database⁶⁰, we find existing US Food and Drug Administration (FDA)-333 approved drugs that target these proteins identified by MR-SPI. For example, 334 gemtuzumab ozogamicin is a drug that targets CD33 and has been approved by FDA 335 for acute myeloid leukemia therapy^{61,62}. Besides, pralsetinib and selpercatinib are two 336 RET inhibitors that have been FDA-approved for the treatment of non-small-cell lung 337 cancers^{63,64}. Therefore, these drugs might be potential drug repurposing candidates for 338 the treatment of AD. 339

340

In Figure 4(B), we present the 3D structural alterations of CD33 due to missense genetic 341 variation of pQTL rs2455069, as predicted by AlphaFold3^{42,43,45}. The 3D structures are 342 shown in blue when the allele is A, and in red when the allele is G at pQTL rs2455069 343 A/G, which is a cis-SNP located on chromosome 19 (19q13.41) and is selected as a 344 valid IV by MR-SPI. The presence of the G allele at pQTL rs2455069 results in the 345 substitution of the 69th amino acid of CD33, changing it from Arginine (colored in 346 347 green if the allele is A) to Glycine (colored in yellow if the allele is G), consequently causing a local change in the structure of CD33 (R69G). Previous studies have found 348 that CD33 is overexpressed in microglial cells in the brain⁶⁵, and the substitution of 349 Arginine to Glycine in the 69th amino acid of CD33 might lead to the accumulation of 350 amyloid plaques in the brain⁶⁶, thus the presence of the G allele at pQTL rs2455069 351 might contribute to an increased risk of AD. We also apply AlphaFold3 to predict the 352 3D structures of the other proteins that are detected to be significantly associated with 353 AD by MR-SPI, which are presented in Supplementary Figure S16. 354

355

In Figure 4(C), we present the point estimates and 95% confidence intervals of the 356 causal effects (on the log odds ratio scale) of these 7 proteins on AD using the other 357 competing MR methods. In Figure 4(C), these proteins are identified by most of the 358 competing MR methods, confirming the robustness of our findings. To the best of our 359 knowledge, there may be two reasons for the differences in results between MRMix 360 361 and other MR methods for some proteins: (1) MRMix assumes that the pQTL-protein and pQTL-outcome associations follow a bivariate normal-mixture model with four 362 363 mixture components while the contamination mixture models assume that the ratio estimator follows a normal distribution with two mixture components, and therefore it 364 may be more challenging to obtain reliable causal effect estimates using the MRMix 365 366 model with a small number of pQTLs per protein; and (2) the default grid search values implemented in the MRMix R package might not be optimal for some proteins. Notably, 367 MR-SPI detects one possibly invalid IV pQTL rs10919543 for TREM2-AD 368 relationship, which is associated with red blood cell count according to PhenoScanner⁶⁷. 369 Red blood cell count is a known risk factor for AD^{68,69}, and thus pQTL rs10919543 370 might exhibit pleiotropy in the relationship of TREM2 on AD. After excluding this 371 potentially invalid IV, MR-SPI suggests that TREM2 is negatively associated with the 372 risk of AD ($\hat{\beta} = -0.04$, *p*-value= 1.20×10^{-18}). Additionally, we perform the gene 373 server⁷⁰ ontology (GO) enrichment analysis using the g:Profiler web 374 375 (https://biit.cs.ut.ee/gprofiler/gost) to gain more biological insights for the 7 proteins 376 identified by MR-SPI, and the results are presented in Figure 4(D) and Supplementary Table S7. After Bonferroni correction, the GO analysis indicates that these 7 proteins 377 are significantly enriched in 20 GO terms, notably, the positive regulation of 378 phosphorus metabolic process and major histocompatibility complex (MHC) class I 379 protein binding. It has been found that increased phosphorus metabolites (e.g., 380 381 phosphocreatine) are associated with aging, and that defects in metabolic processes for phospholipid membrane function is involved in the pathological progression of 382 Alzheimer's disease^{71,72}. In addition, MHC class I proteins may play a crucial role in 383 384 preserving brain integrity during post-developmental stages, and modulation of the stability of MHC class I proteins emerges as a potential therapeutic target for restoring 385 synaptic function in AD⁷³⁻⁷⁵. 386

387

3. Discussion 388

In this paper, we develop a novel integrated pipeline that combines our proposed MR-389 SPI method with AlphaFold3 to identify putative causal protein biomarkers for complex 390

traits/diseases and to predict the 3D structural alterations induced by missense pQTL 391 IVs. Specifically, MR-SPI is an automatic algorithm to select valid pQTL IVs under the 392 plurality rule condition for a specific protein-outcome pair from two-sample GWAS 393 summary statistics. MR-SPI first selects relevant pQTL IVs with strong pQTL-protein 394 associations to minimize weak IV bias, and then applies the proposed voting procedure 395 396 to select valid pQTL IVs whose ratio estimates are similar to each other. In the possible presence of locally invalid IVs in finite-sample settings, MR-SPI further provides a 397 robust confidence interval constructed by the searching and sampling method⁴⁹, which 398 is immune to finite-sample IV selection error. The valid pQTL IVs selected by MR-SPI 399 serve dual purposes: (1) facilitating more reliable scientific discoveries in identifying 400 401 putative causal proteins associated with diseases; and (2) shedding new light on the molecular-level mechanism of causal proteins in disease etiology through the 3D 402 structural alterations of mutated proteins induced by missense pQTL IVs. We employ 403 MR-SPI to conduct xMR analysis with 912 plasma proteins using the proteomics data 404 in 54,306 UK Biobank participants and identify 7 proteins significantly associated with 405 the risk of Alzheimer's disease. The 3D structural changes in these proteins, as predicted 406 by AlphaFold3 in response to missense genetic variations of selected pQTL IVs, 407 offering new insights into their biological functions in the etiology of Alzheimer's 408 disease. We also found existing FDA-approved drugs that target some of our identified 409 410 proteins, which provide opportunities for potential existing drug repurposing for the treatment of Alzheimer's disease. These findings highlight the great potential of our 411 proposed pipeline for identifying protein biomarkers as new therapeutic targets and 412 drug repurposing for disease prevention and treatment. 413

414

415 We emphasize three main advantages of MR-SPI. First, MR-SPI incorporates both proteomics and outcome data to automatically select a set of valid pQTL instruments 416 in genome-wide studies, and the selection procedure does not rely on any additional 417 distributional assumptions on the genetic effects nor require a large number of candidate 418 IVs. Therefore, MR-SPI is the first method to offer such a practically robust approach 419 420 to selecting valid pQTL IVs for a specific exposure-outcome pair from GWAS studies for more reliable MR analyses, which is especially advantageous in the presence of 421 wide-spread horizontal pleiotropy and when only a small number of candidate IVs are 422 423 available in xMR studies. While our real data application specifically focuses on the 424 identification of putative causal protein biomarkers for Alzheimer's disease through the 425 integration of MR-SPI with AlphaFold3, it's important to highlight that MR-SPI holds

broader applicability in elucidating causal relationships across complex traits and 426 diseases. For additional data analysis results and insights into the utility of MR-SPI in 427 this context, please refer to Supplementary Sections S9 and S10. Second, we propose a 428 robust confidence interval for the causal effect using the searching and sampling 429 method, which is immune to finite-sample IV selection error. Therefore, when locally 430 431 invalid IVs are incorrectly selected, MR-SPI can still provide reliable statistical inference for the causal effect using the proposed robust confidence interval. Third, 432 433 MR-SPI is computationally efficient. The average computation time for constructing the standard CI and the robust CI with 20 candidate IVs is 0.02 seconds and 10.60 434 seconds, respectively, using a server equipped with an Intel Xeon Silver 4116 CPU and 435 436 64 GB RAM memory.

437

In conclusion, MR-SPI is a powerful tool for identifying putative causal protein 438 biomarkers for complex traits and diseases. The integration of MR-SPI with 439 AlphaFold3 as a computationally efficient pipeline can further predict the 3D structural 440 441 alterations caused by missense pQTL IVs, improving our understanding of molecular-442 level disease mechanisms. Therefore, our pipeline holds promising implications for drug target discovery, drug repurposing, and therapeutic development. 443

444

445 Limitations of the Study

446 MR-SPI has some limitations. First, MR-SPI uses independent pQTLs as candidate IVs after LD clumping, which might exclude strong and valid pQTL IVs. We plan to extend 447 MR-SPI to include correlated pQTLs with arbitrary LD structure to increase statistical 448 power. Second, the proposed robust confidence interval is slightly more conservative, 449 which is the price to pay for the gained robustness to finite-sample IV selection error. 450 451 We plan to construct less conservative confidence intervals with improved power to detect more putative causal proteins. Third, we will incorporate colocalization 452 analysis⁷⁶⁻⁷⁹ into our pipeline to better understand the shared genetic architecture 453 454 between proteins and disease outcomes when unfiltered GWAS summary statistics are available in future studies. 455

456

4. Resource Availability 457

Lead Contact 458

Further information and requests for resources and reagents should be directed to and 459

will be fulfilled by the lead contact, Zhonghua Liu (<u>zl2509@cumc.columbia.edu</u>) 460

461				
462	Materials Availability			
463	The materials that support the findings of this study are available from the			
464	corresponding authors upon reasonable request. Please contact the lead contact,			
465	Zhonghua Liu (zl2509@cumc.columbia.edu) for additional information.			
466				
467	Data and Code Availability			
468	All the GWAS data analyzed are publicly available with the following URLs:			
469	• GWAS for Alzheimer's disease: <u>https://ctg.cncr.nl/software/summary_statistics;</u>			
470	• UK Biobank proteomics data:			
471	https://www.biorxiv.org/content/10.1101/2022.06.17.496443v1.supplementary-			
472	material			
473	The R package MR.SPI is publicly available at <u>https://github.com/MinhaoYaooo/MR-</u>			
474	<u>SPI</u> .			
475				
476	5. Acknowledgments			
477	We thank the UK Biobank Pharma Proteomics Project (http://ukb-ppp.gwas.eu/) for			
478	providing the proteomics data. We thank the Center for Neurogenomics and Cognitive			
479	Research (CNCR, https://cncr.nl/) for providing GWAS summary statistics for			
480	Alzheimer's disease.			
481				
482	6. Author Contributions			
483	Conceptualization, Zijian Guo and Zhonghua Liu; methodology, Minhao Yao, Zijian			
484	Guo and Zhonghua Liu; software, Minhao Yao; formal analysis: Minhao Yao; writing			
485	(original draft), Minhao Yao, Zijian Guo and Zhonghua Liu; writing (review &			
486 487	Zijian Guo and Zhonghua Liu: supervision Zijian Guo and Zhonghua Liu			
488				
489	7. Declaration of Interests			
490	The authors declare no competing interests.			
491				
492	8. Main Figure Titles and Legends			

493



494

495 Main Figure 1. Overview of the pipeline.

First, we apply MR-SPI for each protein to (1) select valid pQTL IVs under the 496 plurality condition, and (2) estimate the causal effect on the outcome of interest. 497 Second, we perform the Bonferroni correction procedure for causal protein 498 identification. Third, for each causal protein biomarker, we apply AlphaFold3 to 499 predict the 3D structural alterations due to missense pQTL IVs selected by MR-SPI. 500 501 502

All rights reserved. No reuse allowed without permission.



503

504 Main Figure 2. The MR-SPI framework.

First, MR-SPI selects relevant IVs with strong pOTL-protein associations. Second, 505 each relevant IV provides a ratio estimate of the causal effect and then receives votes 506 507 on itself to be valid from the other relevant IVs whose degrees of violation of (A2) and (A3) are small under this ratio estimate of causal effect. For example, by 508 assuming pQTL 1 is valid, the slope of the line connecting pQTL 1 and the origin 509 represents the ratio estimate of pOTL 1, and pOTLs 2 and 3 vote for pOTL 1 to be 510 valid because they are close to that line, while pQTLs 4, 5 and 6 vote against it since 511 they are far away from that line. Third, MR-SPI estimates the causal effect by fitting a 512 zero-intercept OLS regression of pQTL-outcome associations on pQTL-protein 513 associations and construct the robust confidence interval using selected valid pQTL 514 IVs in the maximum clique of the voting matrix, which encodes whether two pQTLs 515 mutually vote for each other to be valid IVs. 516

517



518

Main Figure 3. Empirical performance of MR-SPI and the other competing MR 519 methods in simulated data with sample size 5,000. 520

(A) Boxplot of the percent bias in causal effect estimates. (B) Empirical coverage of 521 95% confidence intervals. The black dashed line in (B) represents the nominal level 522

523 (95%). (C) Average lengths of 95% confidence intervals.

- 524
- 525

All rights reserved. No reuse allowed without permission.



526

Main Figure 4. Causal effect estimates, gene ontology analysis and structural alteration prediction for putatively causal proteins.

(A) Volcano plot of associations of plasma proteins with Alzheimer's disease using MR-529 SPI. The horizontal axis represents the estimated effect size (on the log odds ratio scale), 530 and the vertical axis represents the $-\log_{10}(p - value)$. Positive and negative 531 associations are represented by green and red points, respectively. The size of a point is 532 533 proportional to $-\log_{10}(p$ -value). The blue dashed line represents the significance threshold using Bonferroni correction (*p*-value $< 5.48 \times 10^{-5}$). (B) 3D Structural 534 alterations of CD33 predicted by AlphaFold3 due to missense genetic variation of pQTL 535 rs2455069. The ribbon representation of 3D structures of CD33 with Arginine and 536 Glycine at position 69 are colored in blue and red, respectively. The amino acids at 537 position 69 are displayed in stick representation, with Arginine and Glycine colored in 538 green and yellow, respectively. The predicted template modeling (pTM) yields a score 539 of 0.6 for both structures, which suggests that AlphaFold3 provides good predictions 540 for these two 3D structures. (C) Forest plot of significant associations of proteins with 541 Alzheimer's disease identified by MR-SPI. Confidence intervals are clipped to vertical 542 axis limits. (D) Bubble plot of GO analysis results using the 7 significant proteins 543

detected by MR-SPI. The horizontal axis represents the z-score of the enriched GO 544 term, and the vertical axis represents the $-\log_{10}(p$ -value) after Bonferroni correction. 545 Each point represents one enriched GO term. The blue dashed line represents the 546 significance threshold (adjusted p-value< 0.05 after Bonferroni correction). 547

- 548 549
- 9. Main Tables and Legends 550
- 551

552 Main Table 1: Comparison of MR methods and the underlying assumptions for handling invalid IVs. Balanced pleiotropy means on average the pleiotropic effects 553 have zero mean. NOME assumption refers to NO Measurement Error in the exposure 554 555 data.

MR Method	InSIDE assumption	Majority/plurality rule condition	Other distributional assumptions
Random-effects IVW	Required	Not required	Balanced pleiotropy, NOME assumption
MR-Egger	Required	Not required	NOME assumption
MR-RAPS	Required	Not required	Balanced pleiotropy
MR-PRESSO	Required	Majority rule condition	Not required
Weighed median	Not required	Majority rule condition	Not required
Mode-based estimation	Not required	Plurality rule condition	Not required
MRMix	Not required	Plurality rule condition	Direct effects of a SNP on the exposure and outcome follow a mixture of normal distributions
Contamination mixture method	Not required	Plurality rule condition	Ratio estimate of a SNP follow a mixture of normal distributions, NOME assumption
MR-SPI	Not required	Plurality rule condition	Not required

5	5	6
---	---	---

STAR Methods

Key resources table

REAGENT or	SOURCE	IDENTIFIER
RESOURCE		
Deposited data		
UK Biobank proteomics	Sun, et al. ²⁰	http://ukb-ppp.gwas.eu/
data		
Genome-wide association	Jansen, et al. 50	https://www.nature.com/articles/s41588-018-
studies of Alzheimer's		<u>0311-9</u>
disease		
Software and algorithms		
AlphaFold3	Abramson, et	https://alphafoldserver.com
	al. ⁴⁵	
g:Profiler	Raudvere, et	https://biit.cs.ut.ee/gprofiler/gost
	al. ⁷⁰	
MendelianRandomization	Yavorska and	https://github.com/cran/MendelianRandomization
	Burgess ⁸⁰	
MRMix	Qi and	https://github.com/gqi/MRMix
	Chatterjee ³²	
MR-PRESSO	Verbanck, et	https://github.com/rondolab/MR-PRESSO
	al. ²⁹	
MR-RAPS	Zhao, et al. ¹⁶	https://github.com/qingyuanzhao/mr.raps
MR-SPI	This study	https://github.com/MinhaoYaooo/MR-SPI
PLINK	Purcell, et al.	https://www.cog-genomics.org/plink/1.9
	81	
PyMol	PyMOL	https://pymol.org
	Molecular	
	Graphics	

	System	
R	The R	https://www.r-project.org/
	Foundation for	
	Statistical	
	Computing	

564 565

Method details 566

567 Two-sample GWAS summary statistics

Suppose that we obtain p independent pQTLs $\mathbf{Z} = (Z_1, \dots, Z_p)^{\mathsf{T}}$ by using LD 568 clumping that retains one representative pQTL per LD region⁸¹. We also assume that 569 the pQTLs are standardized⁸² such that $\mathbb{E}Z_j = 0$ and $\operatorname{Var}(Z_j) = 1$ for $1 \le j \le p$. 570 Let D denote the exposure and Y denote the outcome. We assume that D and Y571 follow the exposure model $D = \mathbf{Z}^{\mathsf{T}} \boldsymbol{\gamma} + \delta$ and the outcome model $Y = D\beta + \mathbf{Z}^{\mathsf{T}} \boldsymbol{\pi} + \boldsymbol{\zeta}$ 572 *e*, respectively, where β represents the causal effect of interest, $\boldsymbol{\gamma} = (\gamma_1, \dots, \gamma_p)^{\mathsf{T}}$ 573 represents the IV strength, and $\boldsymbol{\pi} = (\pi_1, \cdots, \pi_p)^{\mathsf{T}}$ encodes the violation of 574 assumptions (A2) and (A3)^{83,84}. If assumptions (A2) and (A3) hold for pQTL *j*, then 575 $\pi_i = 0$ and otherwise $\pi_i \neq 0$ (see Supplementary Section S1 for details). The error 576 terms δ and e with respective variances σ_{δ}^2 and σ_{e}^2 are possibly correlated due to 577 unmeasured confounding factors. By plugging the exposure model into the outcome 578 model, we obtain the reduced-form outcome model $Y = \mathbf{Z}^{\mathsf{T}}(\beta \boldsymbol{\gamma} + \boldsymbol{\pi}) + \epsilon$, where $\epsilon =$ 579 $\beta\delta + e$. Let $\mathbf{\Gamma} = (\Gamma_1, \dots, \Gamma_p)^{\mathsf{T}}$ denote the pQTL-outcome associations, then we have 580 $\Gamma = \beta \gamma + \pi$. If $\gamma_j \neq 0$, then pQTL *j* is called a relevant IV. If both $\gamma_j \neq 0$ and $\pi_j =$ 581 0, then pQTL j is called a valid IV. Let $S = \{j: \gamma_i \neq 0, 1 \le j \le p\}$ denote the set of 582 all relevant IVs, and $\mathcal{V} = \{j: \gamma_i \neq 0 \text{ and } \pi_i = 0, 1 \leq j \leq p\}$ denote the set of all valid 583 IVs. The majority rule condition can be expressed as $|\mathcal{V}| > \frac{1}{2}|\mathcal{S}|^{84}$, and the plurality 584 rule condition can be expressed as $|\mathcal{V}| > \max_{c \neq 0} |\{j \in S : \pi_j / \gamma_j = c\}|^{83}$. If the 585 plurality rule condition holds, then valid IVs with the same ratio of pQTL-outcome 586 effect to pQTL-protein effect will form a plurality. Based on this key observation, our 587 proposed MR-SPI selects the largest group of pQTLs as valid IVs with similar ratio 588

estimates of the causal effect using a voting procedure described in detail in the nextsubsection.

Let $\hat{\gamma}_j$ and $\hat{\Gamma}_j$ be the estimated marginal effects of pQTL j on the protein and the 591 outcome, and $\hat{\sigma}_{\gamma_i}$ and $\hat{\sigma}_{\Gamma_i}$ be the corresponding estimated standard errors 592 respectively. Let $\hat{\boldsymbol{\gamma}} = (\hat{\gamma}_1, \cdots, \hat{\gamma}_p)^{\mathsf{T}}$ and $\hat{\boldsymbol{\Gamma}} = (\hat{\Gamma}_1, \cdots, \hat{\Gamma}_p)^{\mathsf{T}}$ denote the vector of 593 estimated pQTL-protein and pQTL-outcome associations, respectively. In the two-594 sample setting, the summary statistics $\{\hat{\gamma}_j, \hat{\sigma}_{\gamma_j}\}_{1 \le j \le n}$ and $\{\hat{\Gamma}_j, \hat{\sigma}_{\Gamma_j}\}_{1 \le j \le n}$ 595 are calculated from two non-overlapping samples with sample sizes n_1 and n_2 596 respectively. When all the pQTLs are independent of each other, the joint asymptotic 597 distribution of $\widehat{\gamma}$ and $\widehat{\Gamma}$ is 598

599
$$\begin{pmatrix} \widehat{\boldsymbol{\gamma}} - \boldsymbol{\gamma} \\ \widehat{\boldsymbol{\Gamma}} - \boldsymbol{\Gamma} \end{pmatrix} \stackrel{d}{\to} N \left[\boldsymbol{0}, \begin{pmatrix} \frac{1}{n_1} \boldsymbol{V}_{\boldsymbol{\gamma}} & \boldsymbol{0} \\ \boldsymbol{0} & \frac{1}{n_2} \boldsymbol{V}_{\boldsymbol{\Gamma}} \end{pmatrix} \right]$$

where the diagonal entries of \mathbf{V}_{γ} and \mathbf{V}_{Γ} are $\mathbf{V}_{\gamma,jj} = \operatorname{Var} (Z_{ij}^2)\gamma_j^2 + \sum_{l\neq j}\gamma_l^2 + \sigma_{\delta}^2$ and $\mathbf{V}_{\Gamma,jj} = \operatorname{Var} (Z_{ij}^2)\Gamma_j^2 + \sum_{l\neq j}\Gamma_l^2 + \sigma_{\epsilon}^2$, respectively, and the off-diagonal entries of V_{γ} and \mathbf{V}_{Γ} are $\mathbf{V}_{\gamma,j_1j_2} = \gamma_{j_1}\gamma_{j_2}$ and $\mathbf{V}_{\Gamma,j_1j_2} = \Gamma_{j_1}\Gamma_{j_2}(j_1 \neq j_2)$, respectively. The derivation of the limit distribution can be found in Supplementary Section S2. Therefore, with the summary statistics of the protein and the outcome, we estimate the covariance matrices $\frac{1}{n_1}\mathbf{V}_{\gamma}$ and $\frac{1}{n_2}\mathbf{V}_{\Gamma}$ as:

606
$$\frac{1}{n_1}\widehat{\mathbf{V}}_{\gamma,j_1j_2} = \begin{cases} \widehat{\sigma}_{\gamma_{j_1}}^2 & \text{if } j_1 = j_2, \\ \frac{1}{n_1}\widehat{\gamma}_{j_1}\widehat{\gamma}_{j_2} & \text{if } j_1 \neq j_2. \end{cases} \text{ and } \frac{1}{n_2}\widehat{\mathbf{V}}_{\Gamma,j_1j_2} = \begin{cases} \widehat{\sigma}_{\Gamma_{j_1}}^2 & \text{if } j_1 = j_2 \\ \frac{1}{n_2}\widehat{\Gamma}_{j_1}\widehat{\Gamma}_{j_2} & \text{if } j_1 \neq j_2 \end{cases}$$
(1)

607 After obtaining $\{\hat{\boldsymbol{\gamma}}, \hat{\mathbf{V}}_{\gamma}, \hat{\boldsymbol{\Gamma}}, \hat{\mathbf{V}}_{\Gamma}\}$, we then perform the proposed IV selection procedure as 608 illustrated in Figure 2 in the main text.

609

610 Selecting valid instruments by voting

611 The first step of MR-SPI is to select relevant pQTLs with large IV strength using

proteomics data. Specifically, we estimate the set of relevant IVs S by: 612

613
$$\hat{\mathcal{S}} = \left\{ 1 \le j \le p : \frac{|\hat{\gamma}_j|}{\hat{\sigma}_{\gamma_j}} > \Phi^{-1} \left(1 - \frac{\alpha^*}{2} \right) \right\}$$
(2)

where $\hat{\sigma}_{\gamma_i}$ is the standard error of $\hat{\gamma}_i$ in the summary statistics, $\Phi^{-1}(\cdot)$ is the 614 quantile function of the standard normal distribution, and α^* is the user-specified 615 threshold with the default value of 1×10^{-6} . This step is equivalent to filtering the 616 pQTLs in the proteomics data with p-value $< \alpha^*$, and is adopted by most of the 617 current two-sample MR methods to select (relevant) genetic instruments for 618 downstream MR analysis. Note that the selected pQTL instruments may not satisfy the 619 IV independence and exclusion restriction assumptions and thus maybe invalid. In 620 contrast, our proposed MR-SPI further incorporates the outcome data to automatically 621 select a set of valid genetic instruments from \hat{S} for a specific protein-outcome pair. 622

Under the plurality rule condition, valid pQTL instruments with the same ratio of 623 pQTL-outcome effect to pQTL-protein effect (i.e., Γ_i/γ_i) will form a plurality and 624 yield "similar" ratio estimates of the causal effect. Based on this key observation, MR-625 SPI selects a plurality of relevant IVs whose ratio estimates are "similar" to each other 626 627 as valid IVs. Specifically, we propose the following two criteria to measure the similarity between the ratio estimates of two pQTLs j and k: 628

C1: We say the kth pQTL "votes for" the *j*th pQTL to be a valid IV if, by assuming 629 the *i*th pQTL is valid, the *k*th pQTL's degree of violation of assumptions (A2) and 630 631 (A3) is smaller than a threshold as in equation (4);

- C2: We say the ratio estimates of two pQTLs j and k are "similar" if they mutually 632 vote for each other to be valid IVs. 633
- The ratio estimate of the *j*th pQTL is defined as $\hat{\beta}^{[j]} = \hat{\Gamma}_i / \hat{\gamma}_i$. By assuming the *j*th 634 pQTL is valid, the plug-in estimate of the kth pQTL's degree of violation of (A2) and 635 (A3) can be obtained by 636

637
$$\hat{\pi}_{k}^{[j]} = \hat{\Gamma}_{k} - \hat{\beta}^{[j]} \hat{\gamma}_{k} = \left(\hat{\beta}^{[k]} - \hat{\beta}^{[j]}\right) \hat{\gamma}_{k}$$
(3)

as we have $\Gamma_k = \beta \gamma_k + \pi_k$ for the true causal effect β , and $\hat{\Gamma}_k = \hat{\beta}^{[k]} \hat{\gamma}_k$ for the ratio 638

estimate $\hat{\beta}^{[k]}$ of the k th pQTL. From equation (3), $\hat{\pi}_{k}^{[j]}$ has two noteworthy 639 implications. First, $\hat{\pi}_{k}^{[j]}$ measures the difference between the ratio estimates of pQTLs 640 j and k (multiplied by the kth pQTL-protein effect estimate $\hat{\gamma}_k$), and a small $\hat{\pi}_k^{[j]}$ 641 implies that the difference scaled by $\hat{\gamma}_k$ is small. Second, $\hat{\pi}_k^{[j]}$ represents the kth IV's 642 degree of violation of assumptions (A2) and (A3) by regarding the *j*th pQTL's ratio 643 estimate $\hat{\beta}^{[j]}$ as the true causal effect, thus a small $\hat{\pi}_k^{[j]}$ implies a strong evidence that 644 the kth IV supports the *i*th IV to be valid. Therefore, we say the kth IV votes for the 645 646 *j*th IV to be valid if:

647
$$\frac{\left|\widehat{\pi}_{k}^{[j]}\right|}{\widehat{\operatorname{SE}}\left(\widehat{\pi}_{k}^{[j]}\right)} \leq \sqrt{\log\min(n_{1}, n_{2})}$$
(4)

648 where $\widehat{SE}\left(\widehat{\pi}_{k}^{[j]}\right)$ is the standard error of $\widehat{\pi}_{k}^{[j]}$, which is given by:

649
$$\widehat{\operatorname{SE}}\left(\widehat{\pi}_{k}^{[j]}\right)$$

$$\boxed{1\left(\frac{1}{2}\left(\widehat{x}_{k}\right)^{2}-\widehat{x}_{k}\right)-1-\left(\widehat{x}_{k}\right)^{2}-\widehat{x}_{k}}$$

$$650 = \sqrt{\frac{1}{n_2} \left(\widehat{\mathbf{V}}_{\Gamma,kk} + \left(\frac{\widehat{\gamma}_k}{\widehat{\gamma}_j} \right)^2 \widehat{\mathbf{V}}_{\Gamma,jj} - 2 \frac{\widehat{\gamma}_k}{\widehat{\gamma}_j} \widehat{\mathbf{V}}_{\Gamma,jk} \right) + \frac{1}{n_1} \left(\widehat{\beta}^{[j]} \right)^2 \left(\widehat{\mathbf{V}}_{\gamma,kk} + \left(\frac{\widehat{\gamma}_k}{\widehat{\gamma}_j} \right)^2 \widehat{\mathbf{V}}_{\gamma,jj} - 2 \frac{\widehat{\gamma}_k}{\widehat{\gamma}_j} \widehat{\mathbf{V}}_{\gamma,jk} \right)$$
(5)

and the term $\sqrt{\log \min(n_1, n_2)}$ in equation (4) ensures that the violation of (A2) and (A3) can be correctly detected with probability one as the sample sizes go to infinity, as shown in Supplementary Section S3.

For each relevant IV in \hat{S} , we collect all relevant IVs' votes on whether it is a valid IV according to equation (4). Then we construct a voting matrix $\hat{\Pi} \in \mathbb{R}^{|\hat{S}| \times |\hat{S}|}$ to summarize the voting results and evaluate the similarity of two pQTLs' ratio estimates according to criterion C2. Specifically, we define the (k, j) entry of $\hat{\Pi}$ as:

658
$$\widehat{\Pi}_{k,j} = I\left(\max\left\{\frac{\left|\widehat{\pi}_{k}^{[j]}\right|}{\widehat{\operatorname{SE}}\left(\widehat{\pi}_{k}^{[j]}\right)}, \frac{\left|\widehat{\pi}_{j}^{[k]}\right|}{\widehat{\operatorname{SE}}\left(\widehat{\pi}_{j}^{[k]}\right)}\right\} \le \sqrt{\log\min(n_{1}, n_{2})}\right)$$
(6)

659 where $I(\cdot)$ is the indicator function such that I(A) = 1 if event A happens and 660 I(A) = 0 otherwise. From equation (6), we can see that the voting matrix $\widehat{\Pi}$ is

symmetric, and the entries of $\hat{\Pi}$ are binary: $\hat{\Pi}_{k,j} = 1$ represents pQTLs *j* and *k* vote for each other to be a valid IV, i.e., the ratio estimates of these two pQTLs are close to each other; $\hat{\Pi}_{k,j} = 0$ represents that they do not. For example, in Figure 2, $\hat{\Pi}_{1,2} =$ 1 since the ratio estimates of pQTLs 1 and 2 are similar, while $\hat{\Pi}_{1,4} = 0$ because the ratio estimates of pQTLs 1 and 4 differ substantially, as pQTLs 1 and 4 mutually "vote against" each other to be valid according to equation (4).

After constructing the voting matrix $\widehat{\mathbf{\Pi}}$, we select the valid IVs by applying 667 majority/plurality voting or finding the maximum clique of the voting matrix⁴⁷. Let 668 $\mathbf{VM}_k = \sum_{j \in S} \widehat{\Pi}_{k,j}$ be the total number of pQTLs whose ratio estimates are similar to 669 pQTL k. For example, $\mathbf{VM}_1 = 3$ in Figure 2, since three pQTLs (including pQTL 1) 670 itself) yield similar ratio estimates to pQTL 1 according to criterion C2. A large VM_k 671 implies strong evidence that pQTL k is a valid IV, since we assume that valid IVs form 672 a plurality of the relevant IVs. Let $\hat{\mathcal{V}}_M = \{k \in \hat{\mathcal{S}}: \mathbf{VM}_k > |\hat{\mathcal{S}}|/2\}$ denote the set of IVs 673 with majority voting, and $\hat{\mathcal{V}}_P = \{k \in \hat{\mathcal{S}} : \mathbf{VM}_k = \max_{l \in \hat{\mathcal{S}}} \mathbf{VM}_l\}$ denote the set of IVs 674 with plurality voting, then the union $\hat{\mathcal{V}} = \hat{\mathcal{V}}_M \cup \hat{\mathcal{V}}_P$ can be a robust estimate of \mathcal{V} in 675 practice. Alternatively, we can also find the maximum clique in the voting matrix as an 676 estimate of \mathcal{V} . A clique in the voting matrix is a group of IVs who mutually vote for 677 each other to be valid, and the maximum clique is the clique with the largest possible 678 number of IVs⁴⁷. 679

680 Estimation and inference of the causal effect

681 After selecting the set of valid pQTL instruments $\hat{\mathcal{V}}$, the causal effect β is estimated 682 by

$$\hat{\beta}_{\text{SPI}} = \frac{\hat{\Gamma}_{\hat{\mathcal{V}}}^T \hat{\gamma}_{\hat{\mathcal{V}}}}{\hat{\gamma}_{\hat{\mathcal{V}}}^T \hat{\gamma}_{\hat{\mathcal{V}}}}$$
(7)

684 where $\hat{\gamma}_{\hat{\nu}}$ and $\hat{\Gamma}_{\hat{\nu}}$ are the estimates of pQTL-protein associations and pQTL-outcome 685 associations of the selected valid IVs in $\hat{\nu}$, respectively. The MR-SPI estimator in 686 equation (7) is the regression coefficient obtained by fitting a zero-intercept ordinary 687 least squares regression of $\hat{\Gamma}_{\hat{\nu}}$ on $\hat{\gamma}_{\hat{\nu}}$. Since the pQTLs are standardized, the genetic

associations $\hat{\gamma}_j$ and $\hat{\Gamma}_j$ are scaled by $\sqrt{2f_j(1-f_j)}$ (compared to the genetic associations calculated using the unstandardized pQTLs, denoted by $\check{\gamma}_j$ and $\check{\Gamma}_j$), where f_j is the minor allele frequency of pQTL *j*. As $f_j(1-f_j)$ is approximately proportional to the inverse variance of $\check{\Gamma}_j$ when each pQTL IV explains only a small proportion of variance in the outcome⁸⁵, the MR-SPI estimator of the causal effect in equation (7) is approximately equal to the inverse-variance weighted estimator²⁷ calculated with $\{\check{\gamma}_j, \check{\Gamma}_j\}_{j \in \hat{\nu}}$.

695 Let $\alpha \in (0,1)$ be the significance level and $z_{1-\alpha/2}$ be the $(1-\alpha/2)$ -quantile of the 696 standard normal distribution, then the $(1-\alpha)$ confidence interval for β is given by:

697
$$CI = \left(\hat{\beta}_{SPI} - z_{1-\frac{\alpha}{2}}\sqrt{\widehat{Var}(\hat{\beta}_{SPI})}, \hat{\beta}_{SPI} + z_{1-\frac{\alpha}{2}}\sqrt{\widehat{Var}(\hat{\beta}_{SPI})}\right)$$
(8)

698 where $\widehat{Var}(\hat{\beta}_{SPI})$ is the estimated variance of $\hat{\beta}_{SPI}$, which can be found in

699 Supplementary Section S4. As $\min\{n_1, n_2\} \to \infty$, we have $\mathbb{P}\left\{\beta \in \left(\hat{\beta}_{SPI} - \beta\right)\right\}$

700
$$z_{1-\frac{\alpha}{2}}\sqrt{\widehat{\operatorname{Var}}(\hat{\beta}_{\mathrm{SPI}})}, \hat{\beta}_{\mathrm{SPI}} + z_{1-\frac{\alpha}{2}}\sqrt{\widehat{\operatorname{Var}}(\hat{\beta}_{\mathrm{SPI}})}\right) \rightarrow 1-\alpha$$
 under the plurality rule

condition, as shown in Supplementary Section S5. Hence, MR-SPI provides a
theoretical guarantee for the asymptotic coverage probability of the confidence interval
under the plurality rule condition.

We summarize the proposed procedure of selecting valid IVs and constructing thecorresponding confidence interval by MR-SPI in Algorithm 1.

706

707 A robust confidence interval via searching and sampling

In finite-sample settings, the selected set of relevant IVs \hat{S} might include some invalid IVs whose degrees of violation of (A2) and (A3) are small but nonzero, and we refer to

710 them as "locally invalid IVs"⁴⁹. When locally invalid IVs exist and are incorrectly

selected into $\hat{\mathcal{V}}$, the confidence interval in equation (8) becomes unreliable, since its

validity (i.e., the coverage probability attains the nominal level) requires that the invalid 712 IVs are correctly filtered out. In practice, we can multiply the threshold 713 $\sqrt{\log \min(n_1, n_2)}$ in the right-hand side of equation (4) by a scaling factor η to 714 examine whether the confidence interval calculated by equation (8) is sensitive to the 715 choice of the threshold. If the confidence interval varies substantially to the choice of 716 the scaling factor η , then there might exist finite-sample IV selection error especially 717 with locally invalid IVs. We demonstrate this issue with two numerical examples 718 presented in Supplementary Figure S14. Supplementary Figure S14(a) shows an 719 example in which MR-SPI provides robust inference across different values of the 720 scaling factor, while Supplementary Figure S14(b) shows an example that MR-SPI 721 722 might suffer from finite-sample IV selection error, as the causal effect estimate and the corresponding confidence interval are sensitive to the choice of the scaling factor η . 723 This issue motivates us to develop a more robust confidence interval. 724

To construct a confidence interval that is robust to finite-sample IV selection error, we borrow the idea of searching and sampling⁴⁹, with main steps described in Supplementary Figure S17. The key idea is to sample the estimators of γ and Γ repeatedly from the following distribution:

729
$$\begin{pmatrix} \widehat{\boldsymbol{\gamma}}^{(m)} \\ \widehat{\boldsymbol{\Gamma}}^{(m)} \end{pmatrix} \sim N \begin{bmatrix} \begin{pmatrix} \widehat{\boldsymbol{\gamma}} \\ \widehat{\boldsymbol{\Gamma}} \end{pmatrix}, \begin{pmatrix} \frac{1}{n_1} \widehat{\boldsymbol{V}}_{\gamma} & \boldsymbol{0} \\ \boldsymbol{0} & \frac{1}{n_2} \widehat{\boldsymbol{V}}_{\Gamma} \end{pmatrix} \end{bmatrix}, m = 1, \cdots, M$$
(9)

where *M* is the number of sampling times (by default, we set M = 1,000). Since $\hat{\gamma}$ and $\hat{\Gamma}$ follow distributions centered at γ and Γ , there exists m^* such that $\hat{\gamma}^{(m^*)}$ and $\hat{\Gamma}^{(m^*)}$ are close enough to the true values γ and Γ when the number of sampling times *M* is sufficiently large, and thus the confidence interval obtained by using $\hat{\gamma}^{(m^*)}$ and $\hat{\Gamma}^{(m^*)}$ instead of $\hat{\gamma}$ and $\hat{\Gamma}$ might have a larger probability of covering β .

For each sampling, we construct the confidence interval by searching over a grid of β values such that more than half of the selected IVs in $\hat{\mathcal{V}}$ are detected as valid. As for the choice of grid, we start with the smallest interval [L, U] that contains all the following intervals:

739
$$\left(\hat{\beta}^{[j]} - \sqrt{\log \min(n_1, n_2)\widehat{\operatorname{Var}}(\hat{\beta}^{[j]})}, \hat{\beta}^{[j]} + \sqrt{\log \min(n_1, n_2)\widehat{\operatorname{Var}}(\hat{\beta}^{[j]})}\right) \text{ for } j \in \hat{\mathcal{V}}(10)$$

where $\hat{\beta}^{[j]}$ is the ratio estimate of the *j* th pQTL IV, $\widehat{\text{Var}}(\widehat{\beta^{[j]}}) = (\widehat{\mathbf{V}}_{\Gamma,jj}/n_2 + 1)$ 740 $(\hat{\beta}^{[j]})^2 \hat{\mathbf{V}}_{\gamma,jj}/n_1)/\hat{\gamma}_j^2$ is the variance of $\hat{\beta}^{[j]}$, and $\sqrt{\log \min(n_1, n_2)}$ serves the same

741 purpose as in equation (4). Then we discretize [L, U] into $\mathcal{B} = \{b_1, b_2, \dots, b_K\}$ as the 742 grid set such that $b_1 = L, b_K = U$ and $|b_{k+1} - b_k| = n_{\min}^{-0.6}$ for $1 \le k \le K - 2$, 743 where $n_{\min} = \min(n_1, n_2)$. We set the grid size $n_{\min}^{-0.6}$ so that the error caused by 744 discretization is smaller than the parametric rate $n_{\min}^{-1/2}$ 745

For each grid value $b \in \mathcal{B}$ and sampling index $1 \le m \le M$, we propose an estimate 746 of π_j by $\hat{\pi}_j^{(m)}(b) = \left(\hat{\Gamma}_j^{(m)} - b\hat{\gamma}_j^{(m)}\right) \cdot I\left(\left|\hat{\Gamma}_j^{(m)} - b\hat{\gamma}_j^{(m)}\right| \ge \lambda \hat{\rho}_j(b,\alpha)\right)$ for $j \in \hat{\mathcal{V}}$, 747 where $\hat{\rho}_j(b,\alpha) = \Phi^{-1} \left(1 - \frac{\alpha}{2|\hat{\nu}|} \right) \sqrt{\left(\widehat{\mathbf{V}}_{\Gamma,jj}/n_2 + b^2 \widehat{\mathbf{V}}_{\gamma,jj}/n_1 \right)}$ is a data-dependent 748 threshold, $\Phi^{-1}(\cdot)$ is the inverse of the cumulative distribution function of the standard 749 normal distribution, $\alpha \in (0,1)$ is the significance level, and $\lambda = (\log \min(n_1, n_2))/(\log (n_1, n_2))/(\log (n_1, n_2))/(\log (n_1, n_2)))$ 750 $M^{\frac{1}{2|V|}}(\lambda < 1$ when M is sufficiently large) is a scaling factor to make the 751 thresholding more stringent so that the confidence interval in each sampling is shorter, 752 as we will show shortly. Here, $\hat{\pi}_{j}^{(m)}(b) = 0$ indicates that the *j*th pQTL is detected as 753 a valid IV in the *m* th sampling if we take $\{\widehat{\gamma}^{(m)}, \widehat{\Gamma}^{(m)}\}$ as the estimates of genetic 754 associations and b as the true causal effect. Let $\widehat{\pi}_{\hat{v}}^{(m)}(b) = \left(\widehat{\pi}_{j}^{(m)}(b)\right)_{j \in \hat{v}}$, then we 755 construct the *m* th sampling's pseudo confidence interval $pCI^{(m)}$ by searching for the 756 smallest and largest $b \in \mathcal{B}$ such that more than half of pQTLs in $\hat{\mathcal{V}}$ are detected to be 757 valid. Define $\beta_{\min}^{(m)} = \min\left\{b \in \mathcal{B}: \|\widehat{\boldsymbol{\pi}}_{\hat{\mathcal{V}}}^{(m)}(b)\|_{0} < |\hat{\mathcal{V}}|/2\right\}$ and $\beta_{\max}^{(m)} = \max\left\{b \in \mathcal{B}: \|\widehat{\boldsymbol{\pi}}_{\hat{\mathcal{V}}}^{(m)}(b)\|_{0} < |\hat{\mathcal{V}}|/2\right\}$ 758 $\mathcal{B}: \|\widehat{\boldsymbol{\pi}}_{\hat{\mathcal{V}}}^{(m)}(b)\|_{0} < |\widehat{\mathcal{V}}|/2\}$, then the *m* th sampling's pseudo confidence interval is 759 constructed as $pCI^{(m)} = \left(\beta_{\min}^{(m)}, \beta_{\max}^{(m)}\right)$. 760

From the definitions of $\hat{\pi}_{i}^{(m)}(b)$ and pCI^(m), we can see that, when λ is smaller, 761 there will be fewer pQTLs in $\hat{\mathcal{V}}$ being detected as valid for a given $b \in \mathcal{B}$, which leads 762 to fewer $b \in \mathcal{B}$ satisfying $\|\widehat{\boldsymbol{\pi}}_{\hat{\mathcal{V}}}^{(m)}(b)\|_{0} < |\hat{\mathcal{V}}|/2$, thus the pseudo confidence interval 763 in each sampling will be shorter. If there does not exist $b \in \mathcal{B}$ such that the majority 764

765 $M: pCI^{(m)} \neq \emptyset$ denote the set of all sampling indexes corresponding to non-empty 766 searching confidence intervals, then the proposed robust confidence interval is given 767 by: 768

769
$$CI^{\text{robust}} = \left(\min_{m \in \mathcal{M}} \beta_{\min}^{(m)}, \max_{m \in \mathcal{M}} \beta_{\max}^{(m)}\right)$$
(11)

We summarize the procedure of constructing the proposed robust confidence interval 770 in Algorithm 2. 771

772

Simulation settings 773

We set the number of candidate IVs p = 10, as the average number of candidate pQTL 774 IVs for the plasma proteins in the UK Biobank proteomics data is around 7.4. We set 775 the sample sizes $n_1 = n_2 = 5,000, 10,000, 20,000, 40,000$, or 80,000. We generate 776 the j th genetic instruments Z_i and X_i independently from a binomial distribution 777 Bin $(2, f_i)$, where $f_i \sim U(0.05, 0.50)$ is the minor allele frequency of pQTL *j*. Then 778 we generate the protein level $\boldsymbol{D} = (D_1, \dots, D_{n_1})^{\mathsf{T}}$ and the outcome $\boldsymbol{Y} = (Y_1, \dots, Y_{n_2})^{\mathsf{T}}$ 779

according to the exposure model and the outcome model, respectively. Finally, we 780 calculate the genetic associations and their corresponding standard errors for the protein 781 and the outcome, respectively. As for the parameters, we fix the causal effect $\beta = 1$, 782 and we consider 4 settings for $\gamma \in \mathbb{R}^p$ and $\pi \in \mathbb{R}^p$: 783

784 (S1): set
$$\gamma = 0.2 \cdot (\mathbf{1}_5, -\mathbf{1}_5)^{\mathsf{T}}$$
 and $\pi = 0.2 \cdot (\mathbf{0}_6, \mathbf{1}_4)^{\mathsf{T}}$.

785 (S2): set
$$\gamma = 0.2 \cdot (\mathbf{1}_5, -\mathbf{1}_5)^{\mathsf{T}}$$
 and $\pi = 0.2 \cdot (\mathbf{0}_4, \mathbf{1}_3, -\mathbf{1}_3)^{\mathsf{T}}$.

786 (S3): set
$$\gamma = 0.2 \cdot (\mathbf{1}_5, -\mathbf{1}_5)^{\mathsf{T}}$$
 and $\pi = 0.2 \cdot (\mathbf{0}_6, \mathbf{1}_2, 0.25, 0.25)^{\mathsf{T}}$.

787 (S4): set
$$\gamma = 0.2 \cdot (\mathbf{1}_5, -\mathbf{1}_5)^{\mathsf{T}}$$
 and $\pi = 0.2 \cdot (\mathbf{0}_4, \mathbf{1}_2, 0.25, \mathbf{1}_2, -0.25)^{\mathsf{T}}$.

Settings (S1) and (S3) satisfy the majority rule condition, while (S2) and (S4) only 788 789 satisfy the plurality rule condition. In addition, (S3) and (S4) simulate the cases where locally invalid IVs exist, as we shrink some of the pQTLs' violation degrees of 790 assumptions (A2) and (A3) down to 0.25 times in these two settings. In total, we run 791 1,000 replications in each setting. 792

794	Implementation of existing MR methods		
795	We compare the performance of MR-SPI with eight other MR methods in simulation		
796	studies and real data analyses. These methods are implemented as follows:		
797	• Random-effects IVW, MR-Egger, the weighted median method, the mode-		
798	based estimation and the contamination mixture method are implemented in the		
799	R package "MendelianRandomization" (<u>https://github.com/cran/</u>		
800	MendelianRandomization). The mode-based estimation is run with "iteration		
801	= 1000". All other methods are run with the default parameters.		
802	• MR-PRESSO is implemented in the R package "MR-PRESSO"		
803	(https://github.com/ rondolab/MR-PRESSO) with outlier test and distortion test.		
804	• MR-RAPS is performed using the R package "mr.raps"		
805	(https://github.com/qingyuanzhao/mr.raps) with the default options.		
806	• MRMix is run with the R package "MRMix" (https://github.com/gqi/MRMix)		
807	using the default options.		
000			

808

793

Alg	Algorithm 1: Selecting pQTL IVs and Performing Causal Inference by MR-SPI		
	Input:	Summary statistics of independent pQTLs $\{\hat{\gamma}_j, \hat{\sigma}_{\gamma_j}, \hat{\Gamma}_j, \hat{\sigma}_{\Gamma_j}\}_{1 \le j \le p};$	
		Sample sizes n_1 for the proteomics data and n_2 for the outcome; Threshold α^* for selecting relevant IVs; Significance level $\alpha \in (0,1)$.	
	Output:	An estimate of the set of valid IVs $\hat{\mathcal{V}}$, the causal effect estimate $\hat{\beta}_{SPI}$ and the corresponding confidence interval CI.	
1	Estimate	the variance-covariance matrices $\widehat{\mathbf{V}}_{\gamma}$ and $\widehat{\mathbf{V}}_{\Gamma}$ as in equation (1);	
2	Select the	set of relevant IVs \hat{S} as in equation (2);	
3	for $j \in \hat{S}$	do	
4		Calculate $\hat{\beta}^{[j]} = \hat{\Gamma}_j / \hat{\gamma}_j$ and $\hat{\pi}_k^{[j]} = \hat{\Gamma}_k - \hat{\beta}^{[j]} \hat{\gamma}_k$ for $k \in \hat{S}$;	
5		Each relevant IV $k \in \hat{S}$ votes for the <i>j</i> th IV to be valid if $\left \hat{\pi}_{k}^{[j]} \right / \widehat{SE} \left(\hat{\pi}_{k}^{[j]} \right) \leq \sqrt{\log \min(n_{1}, n_{2})};$	
6	end		
7	Construct	the symmetric voting matrix $\widehat{\mathbf{\Pi}} \in \mathbb{R}^{ \hat{\mathcal{S}} \times \hat{\mathcal{S}} }$ as in equation (6);	
8	Select the maximum	set of valid IVs $\hat{\mathcal{V}}$ by majority voting, plurality voting or finding the a clique in the voting matrix;	

9 Estimate the causal effect as in equation (7), and construct the corresponding confidence interval as in equation (8) using the selected valid IVs in $\hat{\mathcal{V}}$.

Algorithm 2: Constructing A Robust Confidence Interval via Searching and Sampling

Summary statistics of independent pQTLs $\{\hat{\gamma}_j, \hat{\sigma}_{\gamma_j}, \hat{\Gamma}_j, \hat{\sigma}_{\Gamma_j}\}_{1 \le j \le p}$; **Input:** Sample sizes n_1 for the proteomics data and n_2 for the outcome; Threshold α^* for selecting relevant IVs; Significance level $\alpha \in$ (0,1); Sampling number M.

- **Output:** The robust confidence interval CI^{robust}.
- Estimate the set of valid IVs $\hat{\mathcal{V}}$ as in Algorithm 1; 1
- 2 Construct the initial interval [L, U] as in equation (10) and obtain the corresponding grid set \mathcal{B} ;
- 3 for $m \leftarrow 1$ to M do

Sample $\hat{\gamma}^{(m)}$ and $\hat{\Gamma}^{(m)}$ from the distribution in equation (9);

5 Calculate $\left\{ \widehat{\boldsymbol{\pi}}_{\widehat{\boldsymbol{\mathcal{V}}}}^{(m)}(b) \right\}_{b \in \mathcal{B}}$ by $\widehat{\boldsymbol{\pi}}_{j}^{(m)}(b) = \left(\widehat{\boldsymbol{\Gamma}}_{j}^{(m)} - b \widehat{\boldsymbol{\gamma}}_{j}^{(m)} \right) \cdot$ $I\left(\left|\widehat{\Gamma}_{j}^{(m)}-b\widehat{\gamma}_{j}^{(m)}\right|\geq\lambda\widehat{\rho}_{j}(b,\alpha)\right),j\in\widehat{\mathcal{V}};$

Construct $pCI^{(m)}$ by grid search over \mathcal{B} ; 6

- 7 end
- 8 Construct the robust confidence interval CI^{robust} as in equation (11).

References

- 1. Self, W.K. and Holtzman, D.M. (2023) Emerging diagnostics and therapeutics for Alzheimer disease. *Nature medicine* **29**, 2187-2199.
- Nichols, E. *et al.* (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet Public Health* 7, e105-e125.
- 3. Van Dyck, C.H. *et al.* (2023) Lecanemab in early Alzheimer's disease. *New England Journal of Medicine* **388**, 9-21.
- 4. Sims, J.R. *et al.* (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *Jama* **330**, 512-527.
- 5. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184-185.
- 6. Karran, E. and De Strooper, B. (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. *Nature reviews Drug discovery* **21**, 306-318.
- 7. Khoury, R., Rajamanickam, J. and Grossberg, G.T. (2018) An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. *Therapeutic advances in drug safety* **9**, 171-178.
- Davey Smith, G. and Ebrahim, S. (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* 32, 1--22.
- Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N. and Davey Smith, G. (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Statistics in Medicine* 27, 1133--1163.
- 10. Davey Smith, G. and Hemani, G. (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human Molecular Genetics* **23**, R89--R98.
- 11. Davey Smith, G. and Ebrahim, S. (2004) Mendelian randomization: prospects, potentials, and limitations. *International Journal of Epidemiology* **33**, 30--42.
- 12. Burgess, S., Butterworth, A. and Thompson, S.G. (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic Epidemiology* **37**, 658--665.
- Pierce, B.L. and Burgess, S. (2013) Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *American Journal of Epidemiology* 178, 1177--1184.
- 14. Lawlor, D.A. (2016) Commentary: Two-sample Mendelian randomization: opportunities and challenges. *International Journal of Epidemiology* **45**, 908.
- 15. Slob, E.A.W. and Burgess, S. (2020) A comparison of robust Mendelian randomization methods using summary data. *Genetic Epidemiology* **44**, 313--329.
- Zhao, Q., Wang, J., Hemani, G., Bowden, J. and Small, D.S. (2020) Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *The Annals of Statistics* 48, 1742--1769.
- 17. Morrison, J., Knoblauch, N., Marcus, J.H., Stephens, M. and He, X. (2020) Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. *Nature Genetics* **52**, 740--747.

- Cheng, Q., Zhang, X., Chen, L.S. and Liu, J. (2022) Mendelian randomization accounting for complex correlated horizontal pleiotropy while elucidating shared genetic etiology. *Nature Communications* 13, 1--13.
- 19. Yao, C. *et al.* (2018) Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. *Nature communications* **9**, 3268.
- 20. Sun, B.B. *et al.* (2022) Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants. *BioRxiv*, 2022--06.
- 21. Didelez, V. and Sheehan, N. (2007) Mendelian randomization as an instrumental variable approach to causal inference. *Statistical Methods in Medical Research* **16**, 309--330.
- 22. Sanderson, E., Richardson, T.G., Hemani, G. and Davey Smith, G. (2021) The use of negative control outcomes in Mendelian randomization to detect potential population stratification. *International Journal of Epidemiology* **50**, 1350--1361.
- 23. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M. and Smoller, J.W. (2013) Pleiotropy in complex traits: challenges and strategies. *Nature Reviews Genetics* **14**, 483--495.
- 24. Sivakumaran, S. *et al.* (2011) Abundant pleiotropy in human complex diseases and traits. *The American Journal of Human Genetics* **89**, 607--618.
- 25. Parkes, M., Cortes, A., Van Heel, D.A. and Brown, M.A. (2013) Genetic insights into common pathways and complex relationships among immune-mediated diseases. *Nature Reviews Genetics* **14**, 661--673.
- 26. Schmidt, A.F. *et al.* (2020) Genetic drug target validation using Mendelian randomisation. *Nature Communications* **11**, 3255.
- 27. Bowden, J. *et al.* (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Statistics in Medicine* **36**, 1783--1802.
- 28. Bowden, J., Davey Smith, G. and Burgess, S. (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International Journal of Epidemiology* **44**, 512--525.
- 29. Verbanck, M., Chen, C.-Y., Neale, B. and Do, R. (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature Genetics* **50**, 693--698.
- 30. Bowden, J., Davey Smith, G., Haycock, P.C. and Burgess, S. (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genetic Epidemiology* **40**, 304--314.
- 31. Hartwig, F.P., Davey Smith, G. and Bowden, J. (2017) Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *International Journal of Epidemiology* **46**, 1985--1998.
- 32. Qi, G. and Chatterjee, N. (2019) Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects. *Nature Communications* **10**, 1--10.
- 33. Burgess, S., Foley, C.N., Allara, E., Staley, J.R. and Howson, J.M.M. (2020) A robust and efficient method for Mendelian randomization with hundreds of genetic variants. *Nature Communications* **11**, 1--11.
- 34. He, B., Shi, J., Wang, X., Jiang, H. and Zhu, H.-J. (2020) Genome-wide pQTL analysis of protein expression regulatory networks in the human liver. *BMC biology* **18**, 1-16.
- 35. Swerdlow, D.I. *et al.* (2016) Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *International Journal of Epidemiology* **45**, 1600--

1616.

- 36. Zaneveld, J.R., McMinds, R. and Vega Thurber, R. (2017) Stress and stability: applying the Anna Karenina principle to animal microbiomes. *Nature microbiology* **2**, 1-8.
- 37. Shriner, D. and Rotimi, C.N. (2018) Whole-genome-sequence-based haplotypes reveal single origin of the sickle allele during the holocene wet phase. *The American Journal of Human Genetics* **102**, 547-556.
- 38. Karki, R., Pandya, D., Elston, R.C. and Ferlini, C. (2015) Defining "mutation" and "polymorphism" in the era of personal genomics. *BMC medical genomics* **8**, 1-7.
- 39. Ashley-Koch, A., Yang, Q. and Olney, R.S. (2000) Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. *American journal of epidemiology* **151**, 839-845.
- 40. Rees, D.C., Williams, T.N. and Gladwin, M.T. (2010) Sickle-cell disease. *The Lancet* **376**, 2018-2031.
- 41. Kato, G.J. *et al.* (2018) Sickle cell disease. *Nature reviews Disease primers* **4**, 1-22.
- 42. Jumper, J. *et al.* (2021) Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589.
- 43. Mirdita, M. *et al.* (2022) ColabFold: making protein folding accessible to all. *Nature methods* **19**, 679-682.
- 44. Wayment-Steele, H.K. *et al.* (2023) Predicting multiple conformations via sequence clustering and AlphaFold2. *Nature*, 1-3.
- 45. Abramson, J. *et al.* (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. *Nature*, 1-3.
- 46. Dunn, O.J. (1961) Multiple comparisons among means. *Journal of the American Statistical Association* **56**, 52--64.
- 47. Ouyang, Q., Kaplan, P.D., Liu, S. and Libchaber, A. (1997) DNA solution of the maximal clique problem. *Science* **278**, 446--449.
- 48. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **57**, 289--300.
- Guo, Z. (2023) Causal inference with invalid instruments: post-selection problems and a solution using searching and sampling. *Journal of the Royal Statistical Society Series B: Statistical Methodology* 85, 959-985.
- 50. Jansen, I.E. *et al.* (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics* **51**, 404--413.
- 51. Naj, A.C. *et al.* (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature genetics* **43**, 436--441.
- 52. Rathore, N. *et al.* (2018) Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease. *PLoS genetics* **14**, e1007427.
- 53. Griciuc, A. *et al.* (2019) TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease. *Neuron* **103**, 820--835.
- 54. Helgadottir, H.T. *et al.* (2019) Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient. *Human Molecular Genetics* **28**, 2675--2685.
- 55. Rimal, S. *et al.* (2023) Reverse electron transfer is activated during aging and contributes

to aging and age-related disease. EMBO reports 24, e55548.

- 56. Winfree, R.L. *et al.* (2023) TREM2 gene expression associations with Alzheimer's disease neuropathology are region-specific: implications for cortical versus subcortical microglia. *Acta Neuropathologica* **145**, 733-747.
- 57. Yang, X. *et al.* (2023) Functional characterization of Alzheimer's disease genetic variants in microglia. *Nature Genetics*, 1-10.
- (2023) UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Research 51, D523-D531.
- 59. Zhou, Y. *et al.* (2022) Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic Acids Research* **50**, D1398-D1407.
- 60. Wishart, D.S. *et al.* (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic acids research* **46**, D1074-D1082.
- 61. Bross, P.F. *et al.* (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. *Clinical cancer research* **7**, 1490-1496.
- 62. Norsworthy, K.J. *et al.* (2018) FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. *The oncologist* **23**, 1103-1108.
- 63. Kim, J. *et al.* (2021) FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. *Clinical Cancer Research* **27**, 5452-5456.
- 64. Bradford, D. *et al.* (2021) FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. *Clinical Cancer Research* **27**, 2130-2135.
- 65. Griciuc, A. *et al.* (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* **78**, 631-643.
- 66. Tortora, F. *et al.* (2022) CD33 rs2455069 SNP: correlation with alzheimer's disease and hypothesis of functional role. *International Journal of Molecular Sciences* **23**, 3629.
- 67. Kamat, M.A. *et al.* (2019) PhenoScanner V2: an expanded tool for searching human genotype--phenotype associations. *Bioinformatics* **35**, 4851--4853.
- 68. Faux, N.G. *et al.* (2014) An anemia of Alzheimer's disease. *Molecular Psychiatry* **19**, 1227--1234.
- 69. Winchester, L.M., Powell, J., Lovestone, S. and Nevado-Holgado, A.J. (2018) Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease. *Genome Medicine* **10**, 1--12.
- 70. Raudvere, U. *et al.* (2019) g: Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Research* **47**, W191--W198.
- Rijpma, A., van der Graaf, M., Meulenbroek, O., Rikkert, M.G.O. and Heerschap, A. (2018)
 Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3dimensional 31P MR spectroscopic imaging study. *NeuroImage: Clinical* 18, 254-261.
- 72. Parasoglou, P. *et al.* (2022) Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease. *Neuroimage: Reports* **2**, 100121.
- 73. Lazarczyk, M.J. *et al.* (2016) Major Histocompatibility Complex class I proteins are critical for maintaining neuronal structural complexity in the aging brain. *Scientific reports* **6**,

26199.

- 74. Kim, M.-S. *et al.* (2023) Neuronal MHC-I complex is destabilized by amyloid-β and its implications in Alzheimer's disease. *Cell & Bioscience* **13**, 181.
- 75. Le Guen, Y. *et al.* (2023) Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1* 04 subtypes. *Proceedings of the National Academy of Sciences* **120**, e2302720120.
- 76. Giambartolomei, C. *et al.* (2014) Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics* **10**, e1004383.
- 77. Barfield, R. *et al.* (2018) Transcriptome wide association studies accounting for colocalization using Egger regression. *Genetic epidemiology* **42**, 418-433.
- Hukku, A. *et al.* (2021) Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations. *The American Journal of Human Genetics* 108, 25-35.
- 79. Zuber, V. *et al.* (2022) Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. *The American Journal of Human Genetics* **109**, 767-782.
- 80. Yavorska, O.O. and Burgess, S. (2017) MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *International journal of epidemiology* **46**, 1734-1739.
- 81. Purcell, S. *et al.* (2007) PLINK: a tool set for whole-genome association and populationbased linkage analyses. *The American Journal of Human Genetics* **81**, 559--575.
- 82. Bulik-Sullivan, B.K. *et al.* (2015) LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics* **47**, 291--295.
- 83. Guo, Z., Kang, H., Tony Cai, T. and Small, D.S. (2018) Confidence intervals for causal effects with invalid instruments by using two-stage hard thresholding with voting. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **80**, 793--815.
- 84. Kang, H., Zhang, A., Cai, T.T. and Small, D.S. (2016) Instrumental variables estimation with some invalid instruments and its application to Mendelian randomization. *Journal of the American statistical Association* **111**, 132-144.
- 85. Burgess, S., Dudbridge, F. and Thompson, S.G. (2016) Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Statistics in medicine* **35**, 1880-1906.